Skip to content

Randomised Controlled Trial comparing the efficacy of Pidotimod versus placebo in children with persistent asthma.

Randomised Controlled Trial Comparing efficacy of Pidotimod versus placebo in addition to inhaled corticosteroid therapy in children with persistent asthma. - PIDO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013405
Enrollment
68
Registered
2018-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Children between 5-12years of age with persistent asthma requiring inhaled corticosteroid therapy

Interventions

Intervention1: PIDOTIMOD GROUP: Children in this group will receive pidotimod syrup (7 ml i.e. 400mg p.o twice a day for 14 days, followed by 7 ml (400mg) p.o once a day for the next 45 days) in addit

Sponsors

Postgraduate Institute Of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed children (5-12 years old) with persistent asthma defined as per Global Initiative for Asthma guideline [ diagnosis is made in children with history of variable respiratory symptoms i.e, wheeze, cough, shortness of breath, chest tightness atleast >twice/week symptoms, >3-4/month nocturnal symptoms, frequent ER visits for asthma and documented expiratory airflow limitation i.e. FEV1 or PEFR 20 which improve upon bronchodilator challenge after adequately ruling out acute and chronic conditions that mimic asthma]

Exclusion criteria

Exclusion criteria: 1. Children who have received asthma preventer therapy (i.e. inhaled corticosteroids or any preventer therapy), for any duration >2 weeks, during the preceding six months. 2. Children suffering from other diseases that can cause wheezing or difficulty breathing viz cystic fibrosis, and chronic lung disease. 3. Children with congenital lung dysplasia; 4. Children with previously diagnosed severe renal failure. 5. Children with autoimmune, or immunodeficiency disorders. 6. Children who have been prescribed any immunomodulator therapy for any condition in the past. 7. Children whose parents are unwilling or unable to adhere to the follow up protocol.

Design outcomes

Primary

MeasureTime frame
Change in PEFR from baseline at the end of 12 weeks of therapy.Timepoint: 4weeks, 8weeks, 12 weeks

Secondary

MeasureTime frame
Comparison of safety of pidotimod verses placebo at each visit.Comparison of Asthma Symptom Score, FEV1 between the intervention groups at follow up.Comparison of Asthma Symptom Score, FEV1 within each group from baseline to each followup visit.Comparison of PEFR between the intervention groups at 4 weeks and 8 weeks.Comparison of FEV1 between the intervention grooup at follow upTimepoint: 4weeks,8weeks,12weeks

Countries

India

Contacts

Public ContactDr Revati Deglurkar

Post Graduate Institute of Medical Education & Research

dr.joseph.l.mathew@gmail.com7087008357

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026